Kicking off 2025 by leaving this platform pretty much for good. Come on over and find me at the other place. @fishburnsimone.bsky.social. You can find there my message to biotechs for the new year. Also on Linkedin https://t.co/yrLsrdGlxk.

So often I hear, “my vote doesn’t make a difference- I’m in a blue/red state.” Not true. The Iowa poll shows that. States change when people turn up. Don’t leave your fate - or democracy - to others. Vote.

I'll be at @fishburnsimone.bsky.social. Come on over.

Before I fully go to @bluesky, a message for everywhere: VOTE. Vote like it matters, because it does. Get other people to vote. And most of all, take your kids to vote. Not less important than soccer practice, baseball games or Halloween. Vote.

And so, with heavy hearts we enter this Jewish New Year. And with more uncertainty and sadness than we have collectively felt for decades. But still the inevitable hope that this will mark a pivot to better days - wishing those who mark it, a good, healthy and peaceful Shana Tova

There's a long-standing discussion about whether research should be hypothesis-driven or hypothesis free. Omics are making unbiased discovery more realistic and industry is opening up to that. But academic incentives aren't aligned. @_Ktktktktk discusses:

I had a fantastic conversation too! @johnvoyler occupies a rare position in biotech of having built a $20B+ company in under 15 years. Some of his lessons, via the podcast (available also on Apple, Spotify and more).

Our Co-Founder, Chairman and CEO, @johnvoyler, recently joined @FishburnSimone on the @BioCentury podcast. They delved into BeiGene's corporate global growth and our innovative pipeline. Tune in to the show to discover more: https://t.co/RIau9L0sF9

The value in mapping genetics to the medical phenome: case studies from @VanderbiltU. Nancy Cox discusses insights from longitudinal EHRs, biobank data, and their value to drug developers: a BioCentury Q&A

John Oyler’s long game at @BeiGeneGlobal: Owning the process from clinical trials to manufacturing. The oncology company's CEO sits down with BioCentury Editor in Chief @FishburnSimone to talk company building and what's next for BeiGene

@BioCentury We’re inspired by @Immunoplayers in his fireside chat about our joint Together for CHANGE initiative to address data and workforce gaps: "This is a dream project to bring together everyone — all pharma, academic partners are invited to join… First we have to build that trust."

RGC’s Gonçalo Abecasis lent his insights during an enlightening panel discussion at @BioCentury Grand Rounds on optimizing data for purpose. He shared that at RGC, “We are big believers that genetic variation leads to good therapies.” #BioCenturyGrandRounds 🧬

This Harvard student speaks the truth. “Zionist” is not a slur. @Harvard students need to stop using it as one. ⁦@thecrimson⁩

Introducting BioCentury's Back to School 2024. Editor in Chief @FishburnSimone and colleagues drill down on picking the right target, and ask can industry solve its biggest bottleneck?

What a heart-wrenching presentation at the DNC by the parents of Hersh Goldberg-Polin, the young hostage currently being held by Hamas in Gaza. "There is a surplus of agony on all sides of the tragic conflict in the Middle East. In a competition of pain, there are no winners."

Building up B cells @Biogen — Jane Grogan discusses her plans for research at the biotech with @FishburnSimone on The #BioCenturyShow

In an exclusive conversation with @BioCentury, Jim Wilson describes how he plans to use newly launched GemmaBio as a vehicle to create a sustainable model for ultrarare disease gene therapies by capitalizing on efficiencies gained from a platform model.

Calling on translational academics! Do you find it hard to meet #biotech VCs and pharmas? Do you have results and an idea that you'd like to showcase? BioCentury's Grand Rounds conference is designed for you. Sept 9-11, Nashville, TN. Find out more: https://t.co/Oiod4taCdY

Greg Verdine, Co-Founder, President & CEO of LifeMine Therapeutics and Professor of Chemistry at Harvard University is joining #BioCenturyGrandRounds to deliver a keynote address: Blowing up the small molecule paradigm. Learn more: https://t.co/N0vhMbMdUL

AZ’s rise in oncology is probably one of biopharma’s all- time top turnaround stories. In this interview with @AstraZeneca oncology head @susanmgalbraith, we discuss what they did: